Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688309 · ClinicalTrials.gov registry record
Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 44
- Enrollment target
NCT02688309: Clinical Trial study, sponsored by Johns Hopkins University.
NCT02688309 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688309 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This study will examine potential factors in the aqueous humor that may contribute to the development or progression of macular edema or fibrosis (due to any underlying disease) in patients suffering from these conditions.
Interventions
- PROCEDURE Surgery
- DRUG Ozurdex
- PROCEDURE Anterior Chamber (AC) Tap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2021-10-28 |
Why NCT02688309 stopped before completion
NCT02688309 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Surgery is the first listed.
NCT02688309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02688309 about?
NCT02688309 is a clinical study titled "Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases". This study will examine potential factors in the aqueous humor that may contribute to the development or progression of macular edema or fibrosis (due to any underlying disease) in patients suffering from these conditions.
What is the current status of trial NCT02688309?
This trial is currently terminated. The enrollment target is 44 participants. The study started on 2015-01-13. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT02688309?
The interventions under investigation include: Surgery (PROCEDURE), Ozurdex (DRUG), Anterior Chamber (AC) Tap (PROCEDURE).
Who is sponsoring clinical trial NCT02688309?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI